Oncolys BioPharma Inc. (TYO:4588)
Japan · Delayed Price · Currency is JPY 1,873.00
+95.00 (5.34%)
Feb 6, 2026, 3:30 PM JST
Oncolys BioPharma Revenue
Oncolys BioPharma had revenue of 28.55M JPY in the twelve months ending September 30, 2025, down -9.04% year-over-year. In the year 2024, Oncolys BioPharma had annual revenue of 31.38M, down -50.21%.
Revenue (ttm)
28.55M
Revenue Growth
-9.04%
P/S Ratio
1,920.76
Revenue / Employee
679.67K
Employees
42
Market Cap
54.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38M | -31.65M | -50.21% |
| Dec 31, 2023 | 63.04M | -913.14M | -93.54% |
| Dec 31, 2022 | 976.18M | 333.69M | 51.94% |
| Dec 31, 2021 | 642.49M | 328.32M | 104.50% |
| Dec 31, 2020 | 314.18M | -989.67M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takara Bio | 44.08B |
| Nxera Pharma | 28.70B |
| GNI Group | 25.78B |
| RaQualia Pharma | 3.05B |
| Japan Tissue Engineering | 2.26B |
| AnGes | 818.00M |
| Cuorips | 360.00M |
| Healios K.K. | 97.00M |